UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 67

Sortiert nach

Systemic short chain fatty acids limit antitumor effect of CTLA-4 blockade in hosts with cancer

Nature communications, 2020-05, Vol.11 (1), p.2168-2168, Article 2168

2020

Volltextzugriff (PDF)

Tumor-specific Th17-polarized cells eradicate large established melanoma

Blood, 2008-07, Vol.112 (2), p.362-373

2008

Volltextzugriff (PDF)

Adoptively transferred effector cells derived from naïve rather than central memory CD8⁺ T cells mediate superior antitumor immunity

Proceedings of the National Academy of Sciences - PNAS, 2009-10, Vol.106 (41), p.17469-17474

2009

Volltextzugriff (PDF)

Trans-inhibition of activation and proliferation signals by Fc receptors in mast cells and basophils

Science signaling, 2016-12, Vol.9 (459), p.ra126

2016

Volltextzugriff (PDF)

CD8+PD-1+ to CD4+PD-1+ ratio (PERLS) is associated with prognosis of patients with advanced NSCLC treated with PD-(L)1 blockers

Journal for immunotherapy of cancer, 2022-02, Vol.10 (2), p.e004012

2022

Volltextzugriff (PDF)

IL-15 superagonist RLI has potent immunostimulatory properties on NK cells: implications for antimetastatic treatment

Journal for immunotherapy of cancer, 2020-06, Vol.8 (1), p.e000632

2020

Volltextzugriff (PDF)

B cells and the coordination of immune checkpoint inhibitor response in patients with solid tumors

Journal for immunotherapy of cancer, 2024-04, Vol.12 (4), p.e008636

2024

Volltextzugriff (PDF)

Toll-like Receptors in Tumor Immunotherapy

Clinical cancer research, 2007-09, Vol.13 (18), p.5280-5289

2007

Volltextzugriff (PDF)

Overcoming resistance to αPD-1 of MMR-deficient tumors with high tumor-induced neutrophils levels by combination of αCTLA-4 and αPD-1 blockers

Journal for immunotherapy of cancer, 2022-07, Vol.10 (7), p.e005059

2022

Volltextzugriff (PDF)

Murlentamab, a Low Fucosylated Anti-Müllerian Hormone Type II Receptor (AMHRII) Antibody, Exhibits Anti-Tumor Activity through Tumor-Associated Macrophage Reprogrammation and T Cell Activation

Cancers, 2021-04, Vol.13 (8), p.1845

2021

Volltextzugriff (PDF)

A strain of Lactobacillus casei inhibits the effector phase of immune inflammation

The Journal of immunology (1950), 2011-09, Vol.187 (5), p.2646-2655

2011

Volltextzugriff (PDF)

378 Efficacy, safety and ancillary analyses of pembrolizumab in combination with nintedanib for the treatment of patients with relapsed advanced mesothelioma

Journal for immunotherapy of cancer, 2021-11, Vol.9 (Suppl 2), p.A409-A409

2021

Volltextzugriff (PDF)

Circulating T-cell Immunosenescence in Patients with Advanced Non-small Cell Lung Cancer Treated with Single-agent PD-1/PD-L1 Inhibitors or Platinum-based Chemotherapy

Clinical cancer research, 2021-01, Vol.27 (2), p.492-503

2021

Volltextzugriff (PDF)

Fcγ receptors inhibit mouse and human basophil activation

The Journal of immunology (1950), 2012-09, Vol.189 (6), p.2995-3006

2012

Volltextzugriff (PDF)

Wnt signaling arrests effector T cell differentiation and generates CD8 + memory stem cells

Nature medicine, 2009-07, Vol.15 (7), p.808-813

2009

Volltextzugriff (PDF)

Phase II and biomarker study of programmed cell death protein 1 inhibitor nivolumab and metronomic cyclophosphamide in paediatric relapsed/refractory solid tumours: Arm G of AcSé-ESMART, a trial of the European Innovative Therapies for Children With Cancer Consortium

European journal of cancer (1990), 2021-06, Vol.150, p.53-62

2021

Volltextzugriff (PDF)

Deep phenotyping of immune cell populations by optimized and standardized flow cytometry analyses

Cytometry. Part A, 2018-08, Vol.93 (8), p.793-802

2018

Volltextzugriff (PDF)

Gefitinib plus tremelimumab combination in refractory non-small cell lung cancer patients harbouring EGFR mutations: The GEFTREM phase I trial

Lung cancer (Amsterdam, Netherlands), 2022-04, Vol.166, p.255-264

2022

Volltextzugriff (PDF)

Colon Immune-Related Adverse Events: Anti-CTLA-4 and Anti-PD-1 Blockade Induce Distinct Immunopathological Entities

Journal of Crohn's and colitis, 2017-10, Vol.11 (10), p.1238-1246

2017

Volltextzugriff (PDF)

Interleukin‐7/Interferon Axis Drives T Cell and Salivary Gland Epithelial Cell Interactions in Sjögren’s Syndrome

Arthritis & rheumatology (Hoboken, N.J.), 2021-04, Vol.73 (4), p.631-640

2021

Volltextzugriff (PDF)

Type 17 CD8+ T cells display enhanced antitumor immunity

Blood, 2009-07, Vol.114 (3), p.596-599

2009

Volltextzugriff (PDF)

Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signaling

The Journal of clinical investigation, 2007-08, Vol.117 (8), p.2197-2204

2007

Volltextzugriff (PDF)

1 – 25 von 67

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(64)
Mit Volltextzugriff
(66)

Publikationsform

Artikel
(67)

Sprache

Englisch
(67)
Japanisch
(6)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Systemic short chain fatty acids limit antitumor effect of CTLA-4 blockade in hosts with cancer

Tumor-specific Th17-polarized cells eradicate large established melanoma

Adoptively transferred effector cells derived from naïve rather than central memory CD8⁺ T cells mediate superior antitumor immunity

Trans-inhibition of activation and proliferation signals by Fc receptors in mast cells and basophils

CD8+PD-1+ to CD4+PD-1+ ratio (PERLS) is associated with prognosis of patients with advanced NSCLC treated with PD-(L)1 blockers

IL-15 superagonist RLI has potent immunostimulatory properties on NK cells: implications for antimetastatic treatment

B cells and the coordination of immune checkpoint inhibitor response in patients with solid tumors

Baseline circulating unswitched memory B cells and B-cell related soluble factors are associated with overall survival in patients with clear cell renal cell carcinoma treated with nivolumab within the NIVOREN GETUG-AFU 26 study

Toll-like Receptors in Tumor Immunotherapy

Overcoming resistance to αPD-1 of MMR-deficient tumors with high tumor-induced neutrophils levels by combination of αCTLA-4 and αPD-1 blockers

Murlentamab, a Low Fucosylated Anti-Müllerian Hormone Type II Receptor (AMHRII) Antibody, Exhibits Anti-Tumor Activity through Tumor-Associated Macrophage Reprogrammation and T Cell Activation

A strain of Lactobacillus casei inhibits the effector phase of immune inflammation

378 Efficacy, safety and ancillary analyses of pembrolizumab in combination with nintedanib for the treatment of patients with relapsed advanced mesothelioma

Circulating T-cell Immunosenescence in Patients with Advanced Non-small Cell Lung Cancer Treated with Single-agent PD-1/PD-L1 Inhibitors or Platinum-based Chemotherapy

Fcγ receptors inhibit mouse and human basophil activation

Wnt signaling arrests effector T cell differentiation and generates CD8 + memory stem cells

Phase II and biomarker study of programmed cell death protein 1 inhibitor nivolumab and metronomic cyclophosphamide in paediatric relapsed/refractory solid tumours: Arm G of AcSé-ESMART, a trial of the European Innovative Therapies for Children With Cancer Consortium

Deep phenotyping of immune cell populations by optimized and standardized flow cytometry analyses

Gefitinib plus tremelimumab combination in refractory non-small cell lung cancer patients harbouring EGFR mutations: The GEFTREM phase I trial

Colon Immune-Related Adverse Events: Anti-CTLA-4 and Anti-PD-1 Blockade Induce Distinct Immunopathological Entities

Interleukin‐7/Interferon Axis Drives T Cell and Salivary Gland Epithelial Cell Interactions in Sjögren’s Syndrome

Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen

Type 17 CD8+ T cells display enhanced antitumor immunity

Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signaling

Predicting immunotherapy outcomes under therapy in patients with advanced NSCLC using dNLR and its early dynamics

Suchergebnisse filtern